Haemostasis April 2025 Journal Club

Keep informed about evolving science and clinical practice with our March 2025 compilation of the latest studies, guidelines, and perspectives in haemostasis.

PERSPECTIVES & REVIEWS

• Ellsworth P, Chen SL, Jones LA, et al. Acquired hemophilia A: a narrative review and management approach in the emicizumab era. J Thromb Haemost. 2025;23(3):824-835. doi:10.1016/j.jtha.2024.09.04
• Reyes Ruiz A, Bhale AS, Venkataraman K, et al. Binding Promiscuity of Therapeutic Factor VIII. Thromb Haemost. 2025;125(3):194-206. doi:10.1055/a-2358-0853
• Scully M, Howells L, Lester WA. Impact of new medications on the treatment of immune TTP. Blood. 2025;145(13):1353-1357. doi:10.1182/blood.2024026390

CLINICAL TRIALS

• Barco S, Jalaie H, Sebastian T, et al. Aspirin Plus Rivaroxaban Versus Rivaroxaban Alone for the Prevention of Venous Stent Thrombosis Among Patients With Post-Thrombotic Syndrome: The Multicenter, Multinational, Randomized, Open-Label ARIVA Trial. Circulation. 2025;151(12):835-846. doi:10.1161/CIRCULATIONAHA.124.073050
• Couturaud F, Schmidt J, Sanchez O, et al. Extended treatment of venous thromboembolism with reduced-dose versus full-dose direct oral anticoagulants in patients at high risk of recurrence: a non-inferiority, multicentre, randomised, open-label, blinded endpoint trial. Lancet. 2025;405(10480):725-735. doi:10.1016/S0140-6736(24)02842-3
• Mahlangu J, Mancuso ME, Fischer K, et al. Extension Study With rVIII-SingleChain in Previously Untreated Patients (PUPs) With Severe Haemophilia A. Haemophilia. 2025;31(2):214-223. doi:10.1111/hae.15151
• Veltkamp R, Korompoki E, Harvey KH, et al. Direct oral anticoagulants versus no anticoagulation for the prevention of stroke in survivors of intracerebral haemorrhage with atrial fibrillation (PRESTIGE-AF): a multicentre, open-label, randomised, phase 3 trial. Lancet. 2025;405(10482):927-936. doi:10.1016/S0140-6736(25)00333-2
• Yamashita Y, Morimoto T, Muraoka N, et al. Rivaroxaban for 18 Months Versus 6 Months in Patients With Cancer and Acute Low-Risk Pulmonary Embolism: An Open-Label, Multicenter, Randomized Clinical Trial (ONCO PE Trial). Circulation. 2025;151(9):589-600. doi:10.1161/CIRCULATIONAHA.124.072758

CASE SERIES & RETROSPECTIVE STUDIES

• Avoine J, Harroche A, Azarnoush S, et al. Acquired factor XI deficiency in paediatrics patients: A French series and review of literature cases. Thromb Res. 2025;247:109282. doi:10.1016/j.thromres.2025.109282
• Cohen AT, Wallenhorst C, Rivera M, et al. Comparison of Clinical Outcomes in Patients with Active Cancer Receiving Rivaroxaban or Low-Molecular-Weight Heparin: The OSCAR-UK Study. Thromb Haemost. 2025;125(3):265-277. doi:10.1055/a-2259-0662
• Deptula J, Olshove V, Oldeen M, et al. Normalizing Anti-Thrombin III for heparin management during routine cardiopulmonary bypass for congenital cardiothoracic surgery: A single institution practice review. Perfusion. 2025;40(2):431-439. doi:10.1177/02676591241239819
• Ettingshausen CE, Lassila R, Escolar G, et al. Plasma-Derived von Willebrand Factor/Factor VIII Concentrate (Haemate P) in von Willebrand Disease: A Systematic Review and Pharmacovigilance Update. Haemophilia. 2025;31(2):247-262. doi:10.1111/hae.15138
• Farkh C, Wicky PH, Perrier-Cornet A, et al. Danaparoid failure in heparin-induced thrombocytopenia due to acquired antithrombin deficiency: A case report. Thromb Res. 2025;247:109280. doi:10.1016/j.thromres.2025.109280
• Franchini M, Pasca S, Mengoli C, et al. Bleeding Episodes in Patients With Haemophilia B Receiving Prophylactic Factor IX Treatment: A Systematic Review and Meta-Analysis. Haemophilia. 2025;31(2):173-186. doi:10.1111/hae.70006
• Hermans C, Lambert C, Lobet S, et al. The impact of emicizumab on the clinical validation of new therapies for haemophilia A. Haemophilia. 2025;31(2):331-333. doi:10.1111/hae.15112
• Herron GC, DeCamillo D, Kong X, et al. Timing of Off-Label Dosing of Direct Oral Anticoagulants in Three Large Health Systems. Thromb Haemost. 2025;125(3):278-285. doi:10.1055/a-2365-8681
• Hou L, Chen X, Xie H, et al. Two patients with protein S deficiency and cerebral venous sinus thrombosis: nonsense mutations of the PROS1 gene may account for these deficiencies. Blood Coagul Fibrinolysis. 2025;36(2):51-57. doi:10.1097/MBC.0000000000001343
• Kamel K, Sardo Infirri S, Riddell A, et al. Factor VIII Antibodies Demonstrate Type I or Type II Kinetics in Acquired Haemophilia A. Haemophilia. 2025;31(2):313-318. doi:10.1111/hae.15144
• Kartal-Kaess M, Pinto F, Labarque V, et al. Hemophilia B Leyden: characteristics and natural history in the International Pediatric Network of Hemophilia Management Registry. J Thromb Haemost. 2025;23(3):921-927. doi:10.1016/j.jtha.2024.12.020
• Khanji C, Nuabor W, Gould T, et al. Systematic Literature Review of Outcomes Associated With Adherence to Haemophilia Drug Therapy. Haemophilia. 2025;31(2):187-206. doi:10.1111/hae.15153
• May JE, Allen AL, Samuelson Bannow BT, et al. Safe and effective anticoagulation use: case studies in anticoagulation stewardship. J Thromb Haemost. 2025;23(3):779-789. doi:10.1016/j.jtha.2024.11.024
• Miele C, D’Auria F, Manfredi L, et al. Pharmacokinetic Studies, Assessing the Efficiency of FVIII/VWF Concentrates and Intravenous Human Immunoglobulin, Revealed the Etiopathogenesis of Acquired von Willebrand Disease in Patient With MGUS. Haemophilia. 2025;31(2):340-342. doi:10.1111/hae.15137
• Suresh N, Kurian B, Jeladharan R, et al. Rare coagulation factor deficiencies: a five-year experience from a single tertiary care center in South India. Blood Coagul Fibrinolysis. 2025;36(2):37-43. doi:10.1097/MBC.0000000000001339
• Wang JJ, Warkentin TE, Schönborn L, et al. VITT-like Monoclonal Gammopathy of Thrombotic Significance. NEJM 2025 doi:10.1056/NEJMoa2415930

RESEARCH

• Auditeau C, Nguyen TS, Devaux F, et al. An Inhibitory Single-Domain Antibody against Protein Z-Dependent Protease Inhibitor Promotes Thrombin Generation in Severe Hemophilia A and FXI Deficiency. Thromb Haemost. 2025;125(3):207-217. doi:10.1055/a-2373-2829
• Luo B, Wu X, Zhu J, et al. Compound heterozygous mutations (p.L68R∗37 and p.T241N) lead to abnormal protein levels and structures in hereditary FVII deficiency. Blood Coagul Fibrinolysis. 2025;36(2):44-50. doi:10.1097/MBC.0000000000001340
• Miranda M, Brandsma E, Robben L, et al. Exploring red blood cells as an antigen delivery system to modulate the immune response towards FVIII in hemophilia A. J Thromb Haemost. 2025;23(3):836-848. doi:10.1016/j.jtha.2024.11.012
• Mishima Y, Okada H, Butt AL, et al. In vitro procoagulant effects of Gla-domainless factor Xa in factor XI-deficient and factor IX-deficient plasma. Thromb Res. 2025;247:109286. doi:10.1016/j.thromres.2025.109286
• Yu J, Waresi M, Zhong H, Wu H, Ge J. 20-HETE induced platelet activation via a GPR75-independent pathway. Thromb Res. 2025;247:109277. doi:10.1016/j.thromres.2025.109277

METHODS

• Gurumurthy G, Reynolds L, Sutherland M, et al. Service evaluation of R90 bleeding and platelet disorders gene panel in thrombocytopenia cases. Br J Haematol. 2025;206(3):930-934. doi:10.1111/bjh.19947
• Josset L, Rezigue H, Nougier C, et al. In vitro combined haemostatic efficacy of emicizumab and extended half-life factor VIII compounds. Haemophilia. 2025;31(2):224-230. doi:10.1111/hae.15131
• Kubo M, Konko K, Kinoshita E, et al. A novel automated chemiluminescent enzyme immunoassay for ADAMTS-13 activity enables accompanying measurements of the inhibitory autoantibodies. J Thromb Haemost. 2025;23(3):957-967. doi:10.1016/j.jtha.2024.11.020
• Pickering W, Robinson M, Cogswell C, et al. Factor VIII Activity and Factor VIII Inhibitors Can Be Measured Accurately in Plasma Containing Mim8 by Using Specific Chromogenic Assays. Haemophilia. 2025;31(2):319-327. doi:10.1111/hae.70007
• Revilla N, Vidal-Laso R, Velasco-Rodríguez D, et al. Can the total thrombus-formation analysis system predict bleeding risk in individuals with VWF levels between 30 and 50 IU/dL?. Thromb Res. 2025;247:109260. doi:10.1016/j.thromres.2025.109260
• Salter B, Moffat K, Carlino S, et al. Evaluation of the MRX PT DOAC assay for detection of clinically relevant factor Xa inhibitor drug levels. J Thromb Haemost. 2025;23(3):989-996. doi:10.1016/j.jtha.2024.12.005
• Takemoto A, Kondo N, Kitajo A, et al. Dielectric blood coagulometry to evaluate coagulation activity in patients prescribed factor Xa inhibitors undergoing elective surgery: A prospective observational study. Thromb Res. 2025;247:109283. doi:10.1016/j.thromres.2025.109283
• Tan JY, Wong WH, Liu W, et al. Effect of lupus anti-coagulant and antiphospholipid antibodies on clot waveform analysis parameters. Thromb Res. 2025;247:109268. doi:10.1016/j.thromres.2025.109268